Post-Marketing Pharmacovigilance and Medical Information Market Report 2025

The post-marketing pharmacovigilance and medical information market size has grown rapidly in recent years. It will grow from $6.16 billion in 2024 to $6.9 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth during the historic period can be attributed to the increasing integration of AI in pharmacovigilance processes, rising demand for outsourced drug safety services, the growing complexity of biopharmaceutical products, a stronger focus on patient-reported outcomes, and enhanced collaboration between regulatory agencies and the pharmaceutical industry.

The post-marketing pharmacovigilance and medical information market size is expected to see rapid growth in the next few years. It will grow to $10.68 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to advancements in drug safety analytics tools, the rising adoption of cloud-based pharmacovigilance solutions, an increasing number of novel therapeutic launches, a stronger emphasis on proactive risk management strategies, and expanding pharmacovigilance requirements in emerging markets. Key trends expected during this period include progress in automated adverse event detection, the development of integrated pharmacovigilance platforms, innovations in real-time safety data monitoring, advancements in patient engagement tools for safety reporting, and the use of predictive analytics for drug risk assessment.

The increasing occurrence of adverse drug reactions is expected to drive the growth of the post-marketing pharmacovigilance and medical information market in the coming years. Adverse drug reactions are harmful or unintended effects that occur when a medication is taken at its recommended dosage for prevention, diagnosis, or treatment. Their incidence is rising as the aging population requires treatment for multiple chronic conditions, leading to the use of several medications at once, which raises the risk of harmful drug interactions and unexpected side effects. Post-marketing pharmacovigilance and medical information help manage these reactions by identifying, tracking, and sharing details on potential side effects after a drug is launched, thereby ensuring its safety and effectiveness. For example, in January 2023, according to Navikenz, a US-based artificial intelligence-focused IT services company, adverse drug reactions in the US are estimated to cause between 200,000 and 400,000 deaths annually, surpassing the toll from stroke and diabetes combined. Additionally, there are approximately 2.7 million cases each year, leading to over 100,000 hospitalizations and more than 15,000 deaths. As a result, the increasing incidence of adverse drug reactions is boosting the growth of the post-marketing pharmacovigilance and medical information market.

Leading companies in the post-marketing pharmacovigilance and medical information market are developing advanced solutions, such as AI-powered pharmacovigilance workflows, to improve the accuracy of adverse event detection and enable real-time safety monitoring for better patient outcomes. These workflows leverage artificial intelligence to automate drug safety monitoring, allowing quicker detection of adverse events and ensuring regulatory compliance. For instance, in January 2024, PubHive Ltd., a UK-based cloud-based software-as-a-service (SaaS) company, launched a centralized Summary of Product Characteristics (SmPC) management system for life science companies and research organizations. This platform consolidates essential drug safety data into a single accessible repository, automates literature monitoring and regulatory reporting, enhances team collaboration, and streamlines compliance processes through advanced AI capabilities. As a result, pharmacovigilance teams can work more efficiently and proactively, safeguarding patient safety while meeting regulatory standards.

In October 2023, Ergomed plc, a UK-based pharmaceutical services company, acquired Panacea Pharma Projects Limited for an undisclosed sum. Through this acquisition, Ergomed aims to expand its pharmacovigilance division, PrimeVigilance, strengthen its service capabilities, and broaden its global presence, supporting its strategy to become a leading provider of pharmacovigilance solutions. Panacea Pharma Projects Limited is a UK-based pharmaceutical consultancy specializing in pharmacovigilance and medical information services, including post-marketing support.

Major players in the post-marketing pharmacovigilance and medical information market are Cencora Inc., Cardinal Health Inc., Accenture plc, Sanofi S.A., Thermo Fisher Scientific Inc., Capgemini SE, Merck & Co. Inc., Cognizant Technology Solutions Corporation, IQVIA Holdings Inc., HCL Technologies Limited, Laboratory Corporation of America Holdings, ICON plc, WuXi AppTec Co. Ltd., Syneos Health Inc., Genpact Limited, Charles River Laboratories International Inc., Parexel International Corporation, Avalere Health LLC, Quanticate Limited, Inizio Consulting LLC.

North America was the largest region in the post-marketing pharmacovigilance and medical information market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in post-marketing pharmacovigilance and medical information market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the post-marketing pharmacovigilance and medical information market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Post-marketing pharmacovigilance refers to the ongoing surveillance of a drug’s safety after it has been released to the market, with the aim of detecting, assessing, and preventing adverse effects or other drug-related problems. Medical information services complement this by providing accurate, scientific, and up-to-date information to healthcare professionals and patients regarding a drug’s use, safety, and effectiveness. Together, these practices protect patient health, ensure regulatory compliance, and improve overall treatment outcomes.

The main types of post-marketing pharmacovigilance and medical information include spontaneous reporting, intensified adverse drug reaction (ADR) reporting, targeted spontaneous reporting, cohort event monitoring, and electronic health record (EHR) mining. Spontaneous reporting refers to healthcare professionals or patients voluntarily observing and reporting unexpected reactions linked to medication use to authorized regulatory bodies. The information is disseminated through various product types, such as books, online media, and journals, and serves a wide range of end users, including hospitals, research organizations, and others.

The post-marketing pharmacovigilance and medical information market research report is one of a series of new reports that provides post-marketing pharmacovigilance and medical information market statistics, including post-marketing pharmacovigilance and medical information industry global market size, regional shares, competitors with a post-marketing pharmacovigilance and medical information market share, detailed post-marketing pharmacovigilance and medical information market segments, market trends and opportunities, and any further data you may need to thrive in the post-marketing pharmacovigilance and medical information industry. This post-marketing pharmacovigilance and medical information market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The post-marketing pharmacovigilance and medical information market includes revenues earned by entities by providing services such as adverse event reporting and management, signal detection and risk assessment, drug safety database, medical call center services, and regulatory compliance support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.